0690.Hk
0690.HK is a pharmaceutical company engaged in the research, development, and commercialization of innovative medicines, primarily in the biotechnology sector.
Business. 0690.HK is a pharmaceutical company engaged in the research, development, and commercialization of innovative medicines, primarily in the biotechnology sector.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
0690.HK is a pharmaceutical company engaged in the research, development, and commercialization of innovative medicines, primarily in the biotechnology sector.
The company maintains a strong capital structure with a debt-to-equity ratio of 0.24, indicating a relatively low reliance on debt financing. Total equity stands at HKD 413.25 million, while total liabilities are HKD 166.56 million. The current ratio of 3.23 suggests robust short-term liquidity, with current assets significantly outpacing current liabilities. Free cash flow of HKD 46.08 million and operating cash flow of HKD 88.79 million further support the company’s liquidity position.
Profitability metrics show a return on equity (ROE) of 22.58% and a return on assets (ROA) of 16.1%, both of which are strong indicators of efficient capital use and asset management. These figures are well above the industry median for ROE and ROA in the biotechnology sector, suggesting the company is outperforming its peers in terms of profitability and asset utilization.
The company’s revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification may expose the company to higher operational and market risks, particularly in the event of regulatory changes or market downturns in its primary operating region.
Looking ahead, the company is projected to maintain a stable growth trajectory, with revenue expected to remain consistent in the next fiscal year. Capital expenditures are negative at HKD -52.23 million, indicating a reduction in investment in physical assets, which may reflect a shift toward cost optimization or a focus on intangible assets such as R&D.
Risk factors include a medium liquidity risk, primarily due to the company’s negative net cash position after accounting for total debt. While dilution risk is currently low, the company’s capital structure and financing decisions will need to be closely monitored for any changes in dilution potential.
Recent filings and transcripts have not disclosed any material events that would significantly alter the company’s financial or operational outlook. However, the company’s ongoing R&D activities and product pipeline remain key areas to watch for future growth and innovation.
- The company maintains a strong liquidity position with a current ratio of 3.23 and positive free cash flow.
- Return on equity and return on assets are significantly above industry medians, indicating strong profitability.
- Revenue is concentrated in a single business segment, increasing exposure to market and regulatory risks.
- Capital expenditures are negative, suggesting a focus on cost control or a shift toward intangible investments.
- Liquidity risk is moderate, and dilution risk is currently low.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 0690.HK Market data — financials · 2026-05-26
Ownership & reference
Leadership
- Leung KingsleyExecutive Chairman of the Board
- Zhi Gang ZhaoChief Executive Officer, Executive Director